First Light Asset Management LLC Increases Stake in Repligen Corporation $RGEN

Key Points

• First Light Asset Management LLC increased its stake in Repligen Corporation by 6.5%, now owning 87,850 shares valued at approximately $11.18 million.
• Several other institutional investors have also increased their holdings in Repligen, with Point72 Asset Management boosting its stake by 183.1% to own 918,623 shares worth about $132.2 million.
• Repligen Corporation's average analyst rating is a "Moderate Buy," with a target price averaging $169.45 based on assessments from multiple research firms.

First Light Asset Management LLC increased its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 6.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 87,850 shares of the biotechnology company's stock after acquiring an additional 5,395 shares during the quarter. Repligen comprises about 1.3% of First Light Asset Management LLC's portfolio, making the stock its 24th largest holding. First Light Asset Management LLC owned approximately 0.16% of Repligen worth $11,178,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. KBC Group NV boosted its position in shares of Repligen by 14.9% during the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after acquiring an additional 329 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new position in shares of Repligen during the first quarter worth $132,000. XTX Topco Ltd boosted its position in shares of Repligen by 34.2% during the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock worth $1,646,000 after acquiring an additional 3,295 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Repligen by 40.1% during the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 274 shares during the last quarter. Finally, TD Asset Management Inc boosted its position in shares of Repligen by 10.9% during the first quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company's stock worth $6,511,000 after acquiring an additional 5,014 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus bought 1,800 shares of Repligen stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.20% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on RGEN. Royal Bank Of Canada restated an "outperform" rating and set a $205.00 target price on shares of Repligen in a research report on Tuesday. Evercore ISI decreased their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Barclays initiated coverage on shares of Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target on the stock. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Wells Fargo & Company decreased their price target on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $169.55.

Repligen Trading Up 3.8%

Shares of RGEN traded up $4.40 during midday trading on Thursday, hitting $120.58. The stock had a trading volume of 841,555 shares, compared to its average volume of 653,366. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52. The firm has a market cap of $6.78 billion, a PE ratio of -482.30, a price-to-earnings-growth ratio of 2.14 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The stock's 50 day moving average is $121.51 and its 200 day moving average is $129.58.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same period in the prior year, the company posted $0.40 EPS. The company's revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts forecast that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.